Increased IRAE risk in Breast Cancer Patients treated with Denosumab + Cancer Immunotherapy

Congratulations to Esther Peluso (Graduate Student) and our wonderful collaborators at City of Hope Alexis LeVee and Karen Tsai for their work evaluating the risk of severe immune related adverse events (IRAEs) and efficacy when checkpoint inhibitor cancer immunotherapy is combined with bone protective agent denosumab, a RANKL inhibitor.

Dr. LeVee will present as a podium talk at the San Antonio Breast Cancer Symposium 2024!